Next Article in Journal
Large Osteophytes over 10 mm at Posterior Medial Femoral Condyle Can Lead to Asymmetric Extension Gap Following Bony Resection in Robotic Arm–Assisted Total Knee Arthroplasty with Pre-Resection Gap Balancing
Next Article in Special Issue
Osteoporosis and Fragility Fractures in Patients with Liver Cirrhosis: Usefulness of FRAX® as a Screening Tool
Previous Article in Journal
Combined Metabolic and Functional Tumor Volumes on [18F]FDG-PET/MRI in Neuroblastoma Using Voxel-Wise Analysis
Previous Article in Special Issue
Histological Characteristics and Management of Hepatitis on Immune Checkpoint Inhibitors: A Retrospective Descriptive Study
 
 
Article
Peer-Review Record

Clinicopathologic Features, Genetics, Treatment, and Long-Term Outcomes in Japanese Children and Young Adults with Benign Recurrent Intrahepatic Cholestasis: A Multicenter Study

J. Clin. Med. 2023, 12(18), 5979; https://doi.org/10.3390/jcm12185979
by Ken Kato 1, Shuichiro Umetsu 2, Takao Togawa 3, Koichi Ito 3, Takayoshi Kawabata 4, Teruko Arinaga-Hino 5, Naoya Tsumura 1, Ryosuke Yasuda 1, Yutaro Mihara 6, Hironori Kusano 6, Shogo Ito 3, Kazuo Imagawa 7, Hisamitsu Hayashi 8, Ayano Inui 2, Yushiro Yamashita 1 and Tatsuki Mizuochi 1,*
Reviewer 1:
Reviewer 2:
J. Clin. Med. 2023, 12(18), 5979; https://doi.org/10.3390/jcm12185979
Submission received: 30 July 2023 / Revised: 13 September 2023 / Accepted: 13 September 2023 / Published: 15 September 2023
(This article belongs to the Collection Clinical Research in Hepatology)

Round 1

Reviewer 1 Report

Thank you this is a good quality report of a case series of patients with BRIC. 

I only have few suggestions:

1. Table 1 and elsewhere: "general education" best to replace with "mainstream education". 

2. line 158 page 4. "simple heterozygous" best to replace here and elsewhere: "only one mutant allele identified". This is because it is possible that the second mutation exists but has not been detected due to difficult sequence or deep intronic mutation. 

3. line 264 page 8 "all told" replace with "altogether". 

4. Were identified mutations reported before and what was the phenotype associated with them?

no other comments. 

Author Response

Journal of Clinical Medicine Editorial Office

 

Dear Editors and Reviewers,

 

RE: jcm-2558703

Title: Clinicopathologic features, genetics, treatment, and long-term outcome in Japanese children and young adults with benign recurrent intrahepatic cholestasis: a multicenter study

 

Thank you very much for your encouraging letter of September 5, 2023. Based on your kind suggestions and those of reviewers concerning our manuscript numbered jcm-2558703 and titled "Clinicopathologic features, genetics, treatment, and long-term outcome in Japanese children and young adults with benign recurrent intrahepatic cholestasis: a multicenter study," my coauthors and I have made revisions as summarized below. We also entered all reviewer-prompted changes in the revised manuscript in red with yellow highlighted. When we could not carry out a suggestion, we explained the reasons for difficulty in this letter.

 

Response to Reviewer #1’s comments:

  1. Table 1 and elsewhere: "general education" best to replace with "mainstream education".

We changed “general education” to “mainstream education.”

 

  1. line 158 page 4. "simple heterozygous" best to replace here and elsewhere: "only one mutant allele identified". This is because it is possible that the second mutation exists but has not been detected due to difficult sequence or deep intronic mutation.

 

We changed "simple heterozygous" to "only one variant allele identified."

 

  1. line 264 page 8 "all told" replace with "altogether".

 

We changed "all told" to "altogether."

 

  1. Were identified mutations reported before and what was the phenotype associated with them?

 

All identified variants in this manuscript were previously reported. We cited previous reports including those variants in Table 1 and Reference. Most previous reports described those variants did not clarify long-term clinical course and it is difficult to accurately diagnose the phenotype of whether it is PFIC or BRIC. In our manuscript, we clarify long-term outcome in Japanese BRIC patients and believe that the genotypes in this paper may help to predict genotype-phenotype correlation in the present and future BRIC patients.

 

We attached the revised manuscript.

 

Reviewer 2 Report

This study provides a well-organized description and analysis of patients with benign recurrent intrahepatic cholestasis in Japan. However, there are also some concerns that the authors need to address.

 

Page 7, line 215 : Treatment for cholestatic attacks

Treatment of patients with cholestasis may vary depending on the physician's judgment. Still, there may be cases where drugs such as UDCA, phenobarbital, rifampicin, and cholestyramine, as mentioned by the author, are prescribed simultaneously. Wouldn't it be challenging to accurately assess the efficacy of a drug when multiple drugs are used simultaneously?

 

I believe that most other sentences and compositions in the article are suitable and can benefit other readers.

Author Response

Journal of Clinical Medicine Editorial Office

 

Dear Editors and Reviewers,

 

RE: jcm-2558703

Title: Clinicopathologic features, genetics, treatment, and long-term outcome in Japanese children and young adults with benign recurrent intrahepatic cholestasis: a multicenter study

 

Thank you very much for your encouraging letter of September 5, 2023. Based on your kind suggestions and those of reviewers concerning our manuscript numbered jcm-2558703 and titled "Clinicopathologic features, genetics, treatment, and long-term outcome in Japanese children and young adults with benign recurrent intrahepatic cholestasis: a multicenter study," my coauthors and I have made revisions as summarized below. We also entered all reviewer-prompted changes in the revised manuscript in red with yellow highlighted. When we could not carry out a suggestion, we explained the reasons for difficulty in this letter.

 

Response to Reviewer #2’s comments:

Page 7, line 215: Treatment for cholestatic attacks

Treatment of patients with cholestasis may vary depending on the physician's judgment. Still, there may be cases where drugs such as UDCA, phenobarbital, rifampicin, and cholestyramine, as mentioned by the author, are prescribed simultaneously. Wouldn't it be challenging to accurately assess the efficacy of a drug when multiple drugs are used simultaneously?

 

Thank you very much for your insightful suggestion. We agree with you and think it is one of the study limitations. We added the sentence of "Several patients received multiple drugs which were used simultaneously" in the paragraph of Treatment for cholestatic attacks.

 

We attached the revised manuscript.

 

Author Response File: Author Response.docx

Back to TopTop